NLS Pharmaceutics AG
NASDAQ:NLSP
NLS Pharmaceutics AG
NASDAQ:NLSP
Price:
0.762
USD
2.97%
Market Closed
Market Cap:
$4.6m
NLS Pharmaceutics AG
Other
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
NLS Pharmaceutics AG
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Other
-$386.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Other
-$294m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-54%
|
|
|
Roche Holding AG
SIX:ROG
|
Other
-CHf1.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
0%
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Other
-CHf87k
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Other
-$4m
|
CAGR 3-Years
83%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
NLSP
Intrinsic Value
0.278
USD
Overvaluation 64%
See Also
What is NLS Pharmaceutics AG's Other?
Other
-386.3k
USD
-386.3k
USD
Based on the financial report for Dec 31, 2024, NLS Pharmaceutics AG's Other amounts to -386.3k USD.
What is NLS Pharmaceutics AG's Other growth rate?
Other CAGR 5Y
-8%
-8%
